云顶新耀医药科技有限公司 EVEREST MEDICINES
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Everest Medicines Announces Interim Results for First Half of 2022 2022-08-24 21:10
Everest Medicines Enters into Agreement with Gilead Sciences for Trodelvy in Asia Territories 2022-08-16 07:15
Everest Medicines Announces Regulatory Update and Strategic Partnership for Xerava™ in Taiwan 2022-08-11 08:00
Everest Medicines Announces European Commission Grants Approval of Kinpeygo® for Adults with Primary IgA Nephropathy to our Partner Calliditas Therapeutics 2022-07-18 08:00
Everest Medicines Announces European Commission Grants Approval of Kinpeygo® for Adults with Primary IgA Nephropathy to our Partner Calliditas Therapeutics 2022-07-18 08:00
Everest Medicines Announces Approval of Trodelvy® in China for Second-Line Metastatic Triple-Negative Breast Cancer 2022-06-10 11:12
Everest Medicines' Licensing Partner Gilead Sciences Announces Positive Results from Phase 3 TROPiCS-02 Study of Trodelvy® in Heavily Pre-treated HR+/HER2- Metastatic Breast Cancer Patients 2022-06-04 20:30
Everest Medicines' Licensing Partner Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod's Potentially Best-in-Class Profile in Ulcerative Colitis 2022-05-24 19:00
Everest Medicines' Licensing Partner Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod's Potentially Best-in-Class Profile in Ulcerative Colitis 2022-05-24 19:00
Everest Medicines Enters into an MOU for Partnership with China Resources Pharmaceutical Group for its mRNA Vaccine Business 2022-04-07 07:30
Everest Medicines Announces that Topline Results from Chinese Subpopulation Consistent With Global Phase 3 NefIgArd Study Part A Analysis 2022-04-06 08:00
Everest Medicines Submits New Drug Application in Hong Kong for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer 2022-03-31 08:00
Everest Medicines Announces that Licensing Partner Pfizer Reports Positive Topline Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients, Underscoring Best-in-Class Potential 2022-03-30 08:00
Everest Medicines Announces Financial Results for Full Year Ended December 31, 2021 2022-03-29 06:30
Everest Medicines to Announce Full-Year 2021 Financial Results on March 29, 2022 2022-03-15 09:00
Everest Medicines Enters into Agreement with Calliditas Therapeutics, Expanding Territory License to Develop and Commercialize NEFECON in South Korea 2022-03-14 08:00
Everest Medicines Announces that Licensing Partner Venatorx Pharmaceuticals Reports Positive Results from Pivotal Phase 3 Cefepime-Taniborbactam Trial 2022-03-10 19:05
Everest Medicines Announces First Drug Approval of Trodelvy® in Singapore for Second-Line Metastatic Triple-Negative Breast Cancer 2022-02-07 08:00
Everest Medicines Enters into a Global Licensing Agreement to Develop and Commercialize Singapore's Experimental Drug Development Centre's 3CL Protease Inhibitors as Potentially Best-in-Class COVID-19 Oral Antiviral Treatments Worldwide 2022-01-14 08:00
Everest Medicines Will Participate in a Clinical Trial with Gilead and MSD to Evaluate Trodelvy® in Combination with KEYTRUDA® (pembrolizumab) in First-Line Metastatic Non-Small Cell Lung Cancer 2022-01-10 21:35
1 2 3 4 5 6 7